Onco-Nephrology
1. Introduction - p. 121 2. Estimation of kidney function - p. 121 3. Platinum-based chemotherapeutics - p. 123 4. Alkylating agents - p. 128 5. Antimetabolites - p. 132 6. Antitumor antibiotics - p. 138 7. Chloroethylnitrosourea compounds carmustine, semustine, streptozocin, bendamustine, estramustine, lomustine - p. 140 8. Microtubule inhibitors - p. 142 9. Topoisomerase inhibitors - p. 142 10. Others - p. 143 11. References - p. 146 12. References - p. 146 13. 17. Targeted cancer therapies (biologics) - p. 146 14. 18. Adverse kidney effects of immunotherapies - p. 158 15. 19. Chemotherapy in chronic kidney disease and dialysis - p. 172 16. 20. Radiation nephropathy - p. 184 17. SECTION 5. Paraneoplastic Glomerulopathies - p. 192 18. 21. Paraneoplastic glomerular diseases - p. 192 19. 22. Paraneoplastic glomerulonephritis - p. 199 20. 23. Hematologic malignancies - p. 205 21. 24. Cancer screening recommendations - p. 211 22. SECTION 6. Renal Tumors - p. 215 23. 25. Renal cell cancer - p. 215 24. 26. Wilms tumor and von Hippel Lindau disease - p. 230 25. 27. Tuberous sclerosis complex and the kidney - p. 237 26. 28. Evaluation of a renal cyst/mass - p. 245 27. SECTION 7. Acute Kidney Injury - p. 255 28. 29. Acute kidney injury incidence, pathogenesis, and outcomes - p. 255 29. 30. Tumor lysis syndrome - p. 260 30. 31. Obstructive nephropathy in cancer - p. 266 31. 32. Renal replacement therapies - p. 275 32. SECTION 8. Chronic Kidney Disease and Cancer - p. 285 33. 33. Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors - p. 285 34. 34. Incidence of cancer and screening recommendations - p. 292 35. 35. Cancer in renal transplant patients - p. 299 36. SECTION 9. Kidney Infections - p. 307 37. 36. Renal infections in cancer patients - p. 307 38. SECTION 10. Infiltrative Diseases - p. 320 39. 37. Kidney disease in leukemia - p. 320 40. 38. Kidney disease in lymphoma - p. 329 41. Index - p. 338
Onco-Nephrology
1. Introduction - p. 121 2. Estimation of kidney function - p. 121 3. Platinum-based chemotherapeutics - p. 123 4. Alkylating agents - p. 128 5. Antimetabolites - p. 132 6. Antitumor antibiotics - p. 138 7. Chloroethylnitrosourea compounds carmustine, semustine, streptozocin, bendamustine, estramustine, lomustine - p. 140 8. Microtubule inhibitors - p. 142 9. Topoisomerase inhibitors - p. 142 10. Others - p. 143 11. References - p. 146 12. References - p. 146 13. 17. Targeted cancer therapies (biologics) - p. 146 14. 18. Adverse kidney effects of immunotherapies - p. 158 15. 19. Chemotherapy in chronic kidney disease and dialysis - p. 172 16. 20. Radiation nephropathy - p. 184 17. SECTION 5. Paraneoplastic Glomerulopathies - p. 192 18. 21. Paraneoplastic glomerular diseases - p. 192 19. 22. Paraneoplastic glomerulonephritis - p. 199 20. 23. Hematologic malignancies - p. 205 21. 24. Cancer screening recommendations - p. 211 22. SECTION 6. Renal Tumors - p. 215 23. 25. Renal cell cancer - p. 215 24. 26. Wilms tumor and von Hippel Lindau disease - p. 230 25. 27. Tuberous sclerosis complex and the kidney - p. 237 26. 28. Evaluation of a renal cyst/mass - p. 245 27. SECTION 7. Acute Kidney Injury - p. 255 28. 29. Acute kidney injury incidence, pathogenesis, and outcomes - p. 255 29. 30. Tumor lysis syndrome - p. 260 30. 31. Obstructive nephropathy in cancer - p. 266 31. 32. Renal replacement therapies - p. 275 32. SECTION 8. Chronic Kidney Disease and Cancer - p. 285 33. 33. Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors - p. 285 34. 34. Incidence of cancer and screening recommendations - p. 292 35. 35. Cancer in renal transplant patients - p. 299 36. SECTION 9. Kidney Infections - p. 307 37. 36. Renal infections in cancer patients - p. 307 38. SECTION 10. Infiltrative Diseases - p. 320 39. 37. Kidney disease in leukemia - p. 320 40. 38. Kidney disease in lymphoma - p. 329 41. Index - p. 338
